Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion.
Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion.
A doctor examining a patient's samples in a modern hospital setting.
In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.
The upfront offer price represents a 27-percent premium over Blueprint's closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025.
The purchase will also include the latter's rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM).
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Intuitive Machines (LUNR) Soars 18.5% on Rosy Prospects from US, China Space Race
We recently published . Intuitive Machines, Inc. (NASDAQ:LUNR) is one of the biggest performers on Wednesday. Intuitive Machines soared by 18.53 percent on Wednesday to end at $13.37 apiece as investors took path from an investment firm's bullish coverage for the company. In a market note, investment bank Craig-Hallum gave a 'buy' recommendation on shares of Intuitive Machines, Inc. (NASDAQ:LUNR) with a price target of $17. The new figure marked a 27-percent upside from its latest closing price. According to Craig-Hallum, Intuitive Machines, Inc. (NASDAQ:LUNR) stands to benefit from the aggressive space race between the United States and China, both of which are targeting to again land humans on the moon by 2030. In other news, Intuitive Machines, Inc.'s (NASDAQ:LUNR) inked a deal with Space Forge for the integration of the latter's semiconductors into its orbital return platform, Zephyr, to support its Earth reentry program. The program is backed by the Texas Space Commission's Space Exploration and Research Fund. Intuitive Machines, Inc. (NASDAQ:LUNR) is scheduled to release the results of its second quarter earnings performance before market open on August 7. While we acknowledge the potential of LUNR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
25 minutes ago
- Yahoo
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the 'LAL'), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@
Yahoo
25 minutes ago
- Yahoo
TSMC Doubles Down On Costly US Chip Builds
Taiwan Semiconductor Manufacturing (NYSE:TSM) is betting big on US fabs even though it costs about 20% more than churning chips out of Taiwan. After a nudge from the Trump administration, its Arizona plant went from blueprint to busy wafer line. At a Washington AI event AMD's Lisa Su admitted that US runs rack up roughly a 20% premium, so clients like AMD and Nvidia (NASDAQ:NVDA) are shelling out 5%20% more just to snap up capacity. Warning! GuruFocus has detected 7 Warning Sign with MSFT. Pricey labor, hefty equipment import fees and a supply chain still finding its footing back home all add up. That said, Su still expects AI accelerator demand to soar toward a $500 B market over the next five years. You get extra supply security but thinner margins for TSMC and its will be watching TSMC's late?July earnings for hints on how they'll tame those cost overruns. This article first appeared on GuruFocus.
